Bolt Biotherapeutics reported financial results for the second quarter ended June 30, 2026. The company generated collaboration revenue of $5,000 and incurred a net loss of $7.7 million. Operating expenses decreased to $8.4 million from $9.2 million in the prior year period due to restructuring and lower research activities. Cash and marketable securities totaled $18.1 million as of June 30, 2026, which management anticipates will fund operations into the first quarter of 2027. Clinically, the Phase 1/2 study for BDC-4182 in gastric and gastroesophageal cancer is ongoing with patients treated in Cohort 4 at 4.0 mg/kg; initial clinical data is expected with third-quarter results. Bolt Biotherapeutics operates as a clinical-stage biopharmaceutical company developing novel immunotherapies, specifically immune-stimulating antibody conjugates, for the treatment of cancer.